CoChat
Sign Up
Cited by 141

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease

Taylor, Matthew, Alessi, Dario R.·2020·Current Opinion in Cell Biology
DOI 10.1016/j.ceb.2020.01.001PMC PMC7262585
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ceb.2020.01.001

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several RABs identified as being controlled by Retromer are substrates for LRRK2-mediated phosphorylation in response to disrupted lysosomal homoeostasis.

    “several RABs identified as being controlled by Retromer are substrates for LRKK2-mediated phosphorylation in response to disrupted lysosomal homoeostasis127–129.”

    From Mapping of endosomal proximity proteomes reveals Retromer as a hub for RAB GTPase regulation (2025) · cites this paper as [128]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 104

  1. Nukada, 1978, [A big family of paralysis agitans (author's transl)], Rinsho Shinkeigaku, 18, 627
  2. Funayama, 2002, A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1, Ann Neurol, 51, 296, 10.1002/ana.10113 · DOI
  3. Zimprich, 2004, Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology, Neuron, 44, 601, 10.1016/j.neuron.2004.11.005 · DOI
  4. Paisan-Ruiz, 2004, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron, 44, 595, 10.1016/j.neuron.2004.10.023 · DOI
  5. Funayama, 2005, An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family, Ann Neurol, 57, 918, 10.1002/ana.20484 · DOI
  6. Gilks, 2005, A common LRRK2 mutation in idiopathic Parkinson's disease, Lancet, 365, 415
  7. Schekman, 2019, Coordinating a new approach to basic research into Parkinson's disease, eLife, 8, e51167, 10.7554/eLife.51167 · DOI
  8. Kalia, 2015, Parkinson's disease, Lancet (London, England), 386, 896, 10.1016/S0140-6736(14)61393-3 · DOI · Paper page
  9. Greggio, 2008, The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation, J Biol Chem, 283, 16906, 10.1074/jbc.M708718200 · DOI
  10. Sen, 2009, Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization, J Biol Chem, 284, 36346, 10.1074/jbc.M109.025437 · DOI
  11. Berger, 2010, Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation, Biochemistry, 49, 5511, 10.1021/bi100157u · DOI
  12. Lis, 2018, Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase, Biochem J, 475, 1, 10.1042/BCJ20170802 · DOI · Paper page
  13. West, 2014, Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents, J Comp Neurol, 522, 2465, 10.1002/cne.23583 · DOI · Paper page
  14. Wauters, 2018, Biochemical and kinetic properties of the complex Roco G-protein cycle, Biol Chem, 10.1515/hsz-2018-0227 · DOI
  15. Gilsbach, 2014, Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation, Front Mol Neurosci, 7, 32, 10.3389/fnmol.2014.00032 · DOI
  16. Ito, 2007, GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease, Biochemistry, 46, 1380, 10.1021/bi061960m · DOI
  17. Purlyte, 2018, Rab29 activation of the Parkinson's disease-associated LRRK2 kinase, EMBO J, 37, 1, 10.15252/embj.201798099 · DOI · Paper page
  18. Cookson, 2010, The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease, Nat Rev Neurosci, 11, 791, 10.1038/nrn2935 · DOI
  19. Farrer, 2007, Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia, Park Relat Disord, 10.1016/j.parkreldis.2006.12.001 · DOI
  20. West, 2005, Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity, Proc Natl Acad Sci U S A, 102, 16842, 10.1073/pnas.0507360102 · DOI · Paper page
  21. Jaleel, 2007, LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity, Biochem J, 405, 307, 10.1042/BJ20070209 · DOI · Paper page
  22. Greggio, 2006, Kinase activity is required for the toxic effects of mutant LRRK2/dardarin, Neurobiol Dis, 23, 329, 10.1016/j.nbd.2006.04.001 · DOI · Paper page
  23. Steger, 2016, Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases, Elife, 5, 10.7554/eLife.12813 · DOI · Paper page
  24. Sheng, 2012, Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations, Sci Transl Med, 4, 164ra161, 10.1126/scitranslmed.3004485 · DOI
  25. Schmidt, 2019, The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGpsi motif in the kinase domain, Proc Natl Acad Sci U S A, 116, 14979, 10.1073/pnas.1900289116 · DOI
  26. Deniston, 2020, Parkinson's Disease-linked LRRK2 structure and model for microtubule interaction, bioRxiv
  27. Nguyen, 2017, Understanding the GTPase activity of LRRK2: regulation, function, and neurotoxicity, Adv Neurobiol, 14, 71, 10.1007/978-3-319-49969-7_4 · DOI
  28. Zhang, 2019, Crystal structure of the WD40 domain dimer of LRRK2, Proc Natl Acad Sci U S A, 116, 1579, 10.1073/pnas.1817889116 · DOI
  29. Nichols, 2010, 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease associated mutations and regulates cytoplasmic localisation, Biochem J, 430, 393, 10.1042/BJ20100483 · DOI
  30. Pellegrini, 2017, Back to the tubule: microtubule dynamics in Parkinson's disease, Cell Mol Life Sci : CMLS, 74, 409, 10.1007/s00018-016-2351-6 · DOI
  31. Kett, 2012, LRRK2 Parkinson disease mutations enhance its microtubule association, Hum Mol Genet, 21, 890, 10.1093/hmg/ddr526 · DOI
  32. Watanabe, 2019, The in situ structure of Parkinson's disease-linked LRRK2, bioRxiv, 837203
  33. Guaitoli, 2016, Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts, Proc Natl Acad Sci U S A, 113, E4357, 10.1073/pnas.1523708113 · DOI
  34. Dzamko, 2010, Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization, Biochem J, 430, 405, 10.1042/BJ20100784 · DOI
  35. Doggett, 2011, Phosphorylation of LRRK2 serines 955 and 973 is disrupted by Parkinson's disease mutations and LRRK2 pharmacological inhibition, J Neurochem
  36. Lobbestael, 2013, Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle, Biochem J, 456, 119, 10.1042/BJ20121772 · DOI
  37. Chen, 2018, Leucine-rich repeat kinase 2 in Parkinson's disease: updated from pathogenesis to potential therapeutic target, Eur Neurol, 79, 256, 10.1159/000488938 · DOI
  38. Alessi, 2018, LRRK2 kinase in Parkinson's disease, Science, 360, 36, 10.1126/science.aar5683 · DOI · Paper page
  39. Di Maio, 2018, LRRK2 activation in idiopathic Parkinson's disease, Sci Transl Med, 10, 10.1126/scitranslmed.aar5429 · DOI
  40. Baptista, 2013, Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs, PloS One, 8, 10.1371/journal.pone.0080705 · DOI
  41. Fuji, 2015, Effect of selective LRRK2 kinase inhibition on nonhuman primate lung, Sci Transl Med, 7, 10.1126/scitranslmed.aaa3634 · DOI
  42. Tong, 2010, Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of {alpha}-synuclein, and apoptotic cell death in aged mice, Proc Natl Acad Sci U S A, 10.1073/pnas.1004676107 · DOI
  43. Herzig, 2011, LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice, Hum Mol Genet, 20, 4209, 10.1093/hmg/ddr348 · DOI
  44. Baptista, 2018, LRRK2 kinase inhibitors induce a reversible effect in the lungs of non-human primates with no measurable pulmonary deficits, bioRxiv, 390815
  45. Whiffin, 2019, Human loss-of-function variants suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson's disease, bioRxiv, 561472
  46. Steger, 2017, Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis, Elife, 6, 10.7554/eLife.31012 · DOI · Paper page
  47. Jeong, 2018, Dysregulated phosphorylation of Rab GTPases by LRRK2 induces neurodegeneration, Mol Neurodegener, 13, 8, 10.1186/s13024-018-0240-1 · DOI
  48. Arranz, 2015, LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism, J Cell Sci, 128, 541
  49. Martin, 2014, Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease, Cell, 157, 472, 10.1016/j.cell.2014.01.064 · DOI · Paper page
  50. Belluzzi, 2016, LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate, Mol Neurodegener, 11, 10.1186/s13024-015-0066-z · DOI · Paper page
  51. Islam, 2016, Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease, Hum Mol Genet, 25, 5365
  52. Kalogeropulou, 2018, P62/SQSTM1 is a novel leucine-rich repeat kinase 2 (LRRK2) substrate that enhances neuronal toxicity, Biochem J, 475, 1271, 10.1042/BCJ20170699 · DOI
  53. Nguyen, 2018, LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson's disease, Proc Natl Acad Sci USA, 115, 5576, 10.1073/pnas.1717590115 · DOI
  54. Müller, 2018, Molecular control of Rab activity by GEFs, GAPs and GDI, Small GTPases, 9, 5, 10.1080/21541248.2016.1276999 · DOI
  55. Pfeffer, 1995, Rab GDP dissociation inhibitor: putting rab GTPases in the right place, J Biol Chem, 270, 17057, 10.1074/jbc.270.29.17057 · DOI
  56. Ito, 2016, Phos-tag analysis of Rab10 phosphorylation by LRRK2: a powerful assay for assessing kinase function and inhibitors, Biochem J, 473, 2671, 10.1042/BCJ20160557 · DOI · Paper page
  57. Karayel, 2019, Accurate MS-based Rab10 phosphorylation stoichiometry determination as readout for LRRK2 activity in Parkinson's disease, bioRxiv, 819607
  58. Fan, 2018, Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils, Biochem J, 475, 23, 10.1042/BCJ20170803 · DOI · Paper page
  59. Mir, 2018, The Parkinson's disease VPS35[D620N] mutation enhances LRRK2 mediated Rab protein phosphorylation in mouse and human, Biochem J, 10.1042/BCJ20180248 · DOI · Paper page
  60. Gomez, 2019, Membrane association but not identity is required for LRRK2 activation and phosphorylation of Rab GTPases, J Cell Biol, jcb, 201902184
  61. Ordóñez, 2019, RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase-mediated centrosomal cohesion and ciliogenesis deficits, Hum Mol Genet, ddz201
  62. Waschbüsch, 2019, Structural basis for Rab8a GTPase recruitment of RILPL2 via LRRK2 phosphorylation of switch 2, STRUCTURE-D-19-00262
  63. Schaub, 2013, The Rilp-like proteins Rilpl1 and Rilpl2 regulate ciliary membrane content, Mol Biol Cell, 24, 453, 10.1091/mbc.e12-08-0598 · DOI
  64. Hanafusa, 2019, LRRK1 phosphorylation of Rab7 at S72 links trafficking of EGFR-containing endosomes to its effector RILP, J Cell Sci, 132, jcs228809, 10.1242/jcs.228809 · DOI
  65. Berndsen, 2019, PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins, eLife, 8, 10.7554/eLife.50416 · DOI · Paper page
  66. Pihlstrom, 2015, Fine mapping and resequencing of the PARK16 locus in Parkinson's disease, J Hum Genet, 60, 357, 10.1038/jhg.2015.34 · DOI · Paper page
  67. MacLeod, 2013, RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk, Neuron, 77, 425, 10.1016/j.neuron.2012.11.033 · DOI · Paper page
  68. Nalls, 2019, Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies, Lancet Neurol, 18, 1091, 10.1016/S1474-4422(19)30320-5 · DOI · Paper page
  69. Liu, 2018, LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network, Hum Mol Genet, 27, 385, 10.1093/hmg/ddx410 · DOI · Paper page
  70. Fujimoto, 2018, Parkinson's disease-associated mutant LRRK2 phosphorylates Rab7L1 and modifies trans-Golgi morphology, Biochem Biophys Res Commun, 495, 1708, 10.1016/j.bbrc.2017.12.024 · DOI
  71. Kuwahara, 2016, LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts, Sci Rep, 6, 29945, 10.1038/srep29945 · DOI · Paper page
  72. Zimprich, 2011, A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease, Am J Hum Genet, 89, 168, 10.1016/j.ajhg.2011.06.008 · DOI · Paper page
  73. Vilarino-Guell, 2011, VPS35 mutations in Parkinson disease, Am J Hum Genet, 89, 162, 10.1016/j.ajhg.2011.06.001 · DOI · Paper page
  74. Deng, 2013, The VPS35 gene and Parkinson's disease, Mov Disord, 28, 569, 10.1002/mds.25430 · DOI
  75. Linhart, 2014, Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2), Mol Neurodegener, 9, 23, 10.1186/1750-1326-9-23 · DOI
  76. Inoshita, 2017, Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila, Hum Mol Genet, 26, 2933, 10.1093/hmg/ddx179 · DOI · Paper page
  77. Hur, 2019, LRRK2 and membrane trafficking: nexus of Parkinson's disease, BMB Rep, 52, 533, 10.5483/BMBRep.2019.52.9.186 · DOI
  78. Hockey, 2015, Dysregulation of lysosomal morphology by pathogenic LRRK2 is corrected by TPC2 inhibition, J Cell Sci, 128, 232
  79. Schapansky, 2018, Familial knockin mutation of LRRK2 causes lysosomal dysfunction and accumulation of endogenous insoluble α-synuclein in neurons, Neurobiol Dis, 111, 26, 10.1016/j.nbd.2017.12.005 · DOI
  80. Eguchi, 2018, LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis, Proc Natl Acad Sci USA, 115, E9115, 10.1073/pnas.1812196115 · DOI
  81. Wallings, 2019, LRRK2 interacts with the vacuolar-type H+-ATPase pump a1 subunit to regulate lysosomal function, Hum Mol Genet, 28, 2696, 10.1093/hmg/ddz088 · DOI
  82. Abu-Remaileh, 2017, Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes, Science (New York, N.Y.), 358, 807, 10.1126/science.aan6298 · DOI
  83. Rocha, 2019, LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease, Neurobiol Dis, 134
  84. Giaime, 2017, Age-dependent dopaminergic neurodegeneration and impairment of the autophagy-lysosomal pathway in LRRK-deficient mice, Neuron, 96, 796, 10.1016/j.neuron.2017.09.036 · DOI
  85. Sidransky, 2012, The link between the GBA gene and parkinsonism, Lancet Neurol, 11, 986, 10.1016/S1474-4422(12)70190-4 · DOI
  86. Ysselstein, 2019, LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson's disease patients, Nat Commun, 10, 10.1038/s41467-019-13413-w · DOI
  87. Liu, 2011, The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease, Nat Immunol, 12, 1063, 10.1038/ni.2113 · DOI
  88. Wallings, 2019, LRRK2 regulation of immune-pathways and inflammatory disease, Biochem Soc Trans, 10.1042/BST20180463 · DOI
  89. Bliederhaeuser, 2016, LRRK2 contributes to monocyte dysregulation in Parkinson's disease, Acta Neuropathol Commun, 4, 10.1186/s40478-016-0396-2 · DOI
  90. Fava, 2019, Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease, Proc Natl Acad Sci USA, 116, 15616, 10.1073/pnas.1901805116 · DOI
  91. Liu, 2017, LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection, J Exp Med, 214, 3051, 10.1084/jem.20170014 · DOI
  92. Härtlova, 2018, LRRK2 is a negative regulator of Mycobacterium tuberculosis phagosome maturation in macrophages, EMBO J, 37, 10.15252/embj.201798694 · DOI
  93. Peter, 2018, Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease, JAMA Neurol, 10.1001/jamaneurol.2018.0605 · DOI · Paper page
  94. Meade, 2019, Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles, Mol Neurodegener, 14, 10.1186/s13024-019-0329-1 · DOI · Paper page
  95. Lin, 2009, Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein, Neuron, 64, 807, 10.1016/j.neuron.2009.11.006 · DOI
  96. Novello S, Arcuri L, Dovero S, Dutheil N, Shimshek DR, Bezard E, Morari M: G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice. Neurobiol Dis 2018, 120:21-33. · DOI
  97. Bieri, 2019, LRRK2 modifies α-syn pathology and spread in mouse models and human neurons, Acta Neuropathol, 137, 961, 10.1007/s00401-019-01995-0 · DOI
  98. Zhao, 2017, LRRK2 antisense oligonucleotides ameliorate α-synuclein inclusion formation in a Parkinson's disease mouse model. Molecular therapy, Nucleic acids, 8, 508, 10.1016/j.omtn.2017.08.002 · DOI
  99. Henderson, 2019, LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice, Acta Neuropathol Commun, 7, 10.1186/s40478-019-0679-5 · DOI
  100. Kalia, 2015, Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease, JAMA neurol, 72, 100, 10.1001/jamaneurol.2014.2704 · DOI
  101. Henderson, 2019, Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease, Acta Neuropathol Commun, 7, 10.1186/s40478-019-0836-x · DOI
  102. Li, 2009, Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease, Nat Neurosci, 12, 826, 10.1038/nn.2349 · DOI
  103. Yue, 2015, Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice, Neurobiol Dis, 78, 172, 10.1016/j.nbd.2015.02.031 · DOI · Paper page
  104. Chen, 2019, Parkinson's disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration, Proc Natl Acad Sci Unit States Am, 116, 5765, 10.1073/pnas.1814909116 · DOI

Cited by

Sorted by citations

Metadata

Authors
Taylor, M., & Alessi, D. R.
ORCID
Taylor, Matthew
Venue
Current Opinion in Cell Biology
Publisher
Elsevier BV
Published
2020-04
Volume
63
Pages
102-113
ISSN
0955-0674
DOI
10.1016/j.ceb.2020.01.001
PMC
PMC7262585
Cited by
141
References
8
Language
en
Licence
Funders
  • GlaxoSmithKline
  • Michael J. Fox Foundation for Parkinson's Research (17298 & 6986)
  • Merck KGaA
  • Stanford University
  • Medical Research Council (MC_UU_12016/2)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review